Diffusion Kurtosis Imaging for Detection of Early Brain Changes in Parkinson's Disease
We aimed to evaluate microscale changes in the bilateral red nucleus and substantia nigra of patients with Parkinson's disease (PD) using diffusion kurtosis imaging (DKI). Twenty-six patients with PD [mean age, 62.5 ± 8.7 years; Hoehn-Yahr stage, 0–4.0; Unified Parkinson's Disease Rating Scale (UPDRS) scores, 8–43] and 15 healthy controls (mean age, 59.5 ± 9.4 years) underwent DKI of the substantia nigra and red nucleus. Imaging was performed using a General Electric (GE) Signa 3.0-T MRI system. Patients with PD were divided into two groups consisting of 12 patients with UPDRS scores ≥ 30 and 14 patients with UPDRS scores
We examined whether Rhy promotes this regulation in bone marrow human mesenchymal stromal cells (BM-hMSCs). Results revealed (i) Rhy modulated biological activity by regulating the mitochondria, N-methyl-D-aspartate receptor subunit, and levels of FGFβ (basic fibroblast growth factor), BDNF (brain-derived neurotrophic factor), OXTR (oxytocin receptor) and ATP (Adenosine triphosphate); (ii) Rhy altered expression level of BM-MSC proliferation/differentiation-related transcription genes; and (iii) interestingly, Rhy amplified the glycolytic flow ratio and lactate dehydrogenase activity while reducing pyruvate dehydrogen...
Parkinson's disease (PD) is the second most common neurodegenerative illness, affecting approximately 1.5 million Americans. Described by many PD patients and families as an insidious “thief,” it progressively diminishes quality-of-life, self-image, and the ability to be independent. The late stage of PD can be protracted with inexorable changes in physical and mental health, altered relationships, and social isolation, all leading to increased suffering. There is significant evidence that many of the greatest needs of PD patients and their caregivers (e.g.
ConclusionThis study showed that PD is a costly neurodegenerative disease that may pose a significant economic burden on patients, health care system and society.
Non-motor symptoms such as cognitive and gastrointestinal (GI) symptoms are common in Parkinson's disease (PD). In PD, GI-symptoms often present prior to motor symptoms. It is hypothesized that GI-symptoms reflect disruptions of the microbiome-gut-brain axis, which leads to altered immune functioning, chronic neuroinflammation, and subsequent neurodegeneration. Initial evidence links gut-dysbiosis to PD pathology and motor symptom severity. The present study examines the longitudinal relationship between severity of GI-symptoms and cognitive impairment in newly diagnosed PD patients.
ConclusionHemoglobin levels in PD seem to be closely related to noradrenergic nervous activity and nigrostriatal dopaminergic degeneration. In contrast to expectations, decreased hemoglobin levels were associated with increased whole-body sympathetic nervous activity in PD.
In this study, we used chemoinformatics tools and molecular docking simulations to analyze molecules that have been experimentally tested and bound to α-synuclein, causing neuroprotective or neurotoxic activity, and whose results have been used to select potential natural neuroprotective molecules. We identified 6 potential natural neuroprotective molecules that are similar in their chemical structure to neuroprotective molecules and have a high number of hydrogen bonds with α-synuclein. We expect that these molecules may lead to the design or discovery of new effective treatments for Parkinson's disease.Graphical abstract
Abbott Laboratories is adding some extra firepower to its neuromodulation offerings. The company said last week that its Infinity Deep Brain Stimulation [DBS] device received a nod from FDA to treat Parkinsonâs disease symptoms. The newly approved indication specifically calls for the Infinity DBS to target an area of the brain called the globus pallidus (GPi). Abbott said the GPi plays an integral role in the motor function and can be targeted with DBS to improve Parkinsonâs disease symptoms not adequately controlled by medication. Abbott said with this approval, the Infinity DBS is now...
Abbott has announced that the FDA has given the company the first ever approval for a device to treat Parkinson’s by delivering deep brain stimulation (DBS) to the internal globus pallidus (GPi), an area associated with motor function. The Infi...
Abbott's Infinity DBS is the first FDA approved directional Deep Brain Stimulation (DBS) system to allow targeting of a specific area of the brain that is critical to motor functions Approximately 60,000 Americans are diagnosed with Parkinson's disease... Devices, Neurology, FDA Abbott, Infinity, Deep Brain Stimulation, Parkinson's Disease
PARKINSON'S DISEASE is a progressive neurological condition that can have a profound impact on your daily life. While it is not known how to prevent the condition, certain lifestyle factors may increase your risk. It may come as a surprise to hear that where you live may also play a role.